Kidney Cancer DNA Registry (NCT02087852)

🧪 Interventions in This Study

• salvia for germline DNA (OTHER)
• the Kidney Cancer Questionnaire (BEHAVIORAL)
• Family History Questionnaire (when applicable) (BEHAVIORAL)
• Blood draw (OTHER)
• Epidemiologic Questionnaire (BEHAVIORAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (7 Sites)

• Memorial Sloan Kettering at Basking Ridge (Consent and Follow-up) — Basking Ridge, New Jersey
• Memorial Sloan Kettering Monmouth (Consent and Follow up) — Middletown, New Jersey
• Memorial Sloan Kettering Bergen (Consent and Follow up ) — Montvale, New Jersey
• Memorial Sloan Kettering Commack (Consent and Follow-up) — Commack, New York
• Memorial Sloan Kettering Westchester (Consent and Follow up) — Harrison, New York
• Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
• Memorial Sloan Kettering Nassau (Consent and Follow-Up) — Uniondale, New York

📞 Contact the Study Coordinator

Phone: (646) 422-4432

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Renal Cancer

• Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment — Los Angeles, California
• Advanced Diffusion Imaging in Renal Cancer Patients — New York, New York
• The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY) — Los Angeles, California
• Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) — La Jolla, California
• Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma — New York, New York
• Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus — Aurora, Colorado

Explore by condition: All Renal Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.